Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cocaine→

Cocaine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-36-2
Molecular formula
C17H21NO4
Molecular weight
303.35 g/mol
Drug class
Ester-type local anaestheticsodium-channel blocker with sympathomimetic activity
Mechanism of action
Blocks voltage-gated sodium channels in neuronal membranes, inhibiting initiation and conduction of nerve impulses and producing local anaesthesia. Cocaine also inhibits catecholamine reuptake and causes local vasoconstriction; these additional effects contribute to cardiovascular and abuse risks.
Indications / reported uses
  • For the specific FDA-approved intranasal cocaine hydrochloride product (GOPRELTO): induction of local anaesthesia of nasal mucous membranes during diagnostic procedures and surgeries on or through the nasal cavities in adults. This is not a general systemic analgesic indication.

Sources: US DailyMed — GOPRELTO (cocaine hydrochloride) prescribing information · FDA label — GOPRELTO · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Ester-type local anaesthetic; sodium-channel blocker with sympathomimetic activity

Mechanism of action

Blocks voltage-gated sodium channels in neuronal membranes, inhibiting initiation and conduction of nerve impulses and producing local anaesthesia. Cocaine also inhibits catecholamine reuptake and causes local vasoconstriction; these additional effects contribute to cardiovascular and abuse risks.

General use cases

  • For the specific FDA-approved intranasal cocaine hydrochloride product (GOPRELTO): induction of local anaesthesia of nasal mucous membranes during diagnostic procedures and surgeries on or through the nasal cavities in adults. This is not a general systemic analgesic indication.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Cocaine Environmental Risk Assessment (ERA) (the Cocaine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.